Good news on the HCQ front
The Henry Ford HCQ study is by no means decisive, but with death rates seemingly halved (sorta, maybe, kinda) — it does show how crazy it is to ban hydroxychloroquine. It also shows it’s low risk, and with all the conflicting studies out there, that there are a lot of ways to stuff things up.
With 10 million cases around the world it seems a bit incongruous that it’s taken so many months to get a trial this basic done with 2,000 patients. Speaking of slow research, the UK hydroxychloroquine trial that stopped has restarted again as of three days ago. This is a trial to see if HCQ can prevent coronavirus in 40,000 healthcare workers.
Perhaps half were saved?
Of those enrolled in the trial, 87% of the people who got hydroxychloroquine (HCQ) survived. This was a lot better than the survival rate of those with neither HCQ nor Azithromycin which was 74%. Possibly half of those who died in the latter group might have been saved had they got HCQ. But, the study was not randomized, so we really don’t know.
Consider that those who got both HCQ and Azithromycin had […]Rating: 10.0/10 (1 vote cast)
July 4, 2020 at 01:14PM